CLEVELAND, Ohio (Oct 21, 2025)—Menopause may take a toll on women physically and emotionally due to declining estrogen levels. For some, the use of hormone therapy has proven valuable in managing bothersome menopause symptoms. A new study suggests that when a woman starts taking hormones makes a major difference in longer term health outcomes. Results of the study will be presented at the 2025 Annual Meeting of The Menopause Society in Orlando October 21-25.

CLEVELAND, Ohio (Oct 21, 2025)—Digestive health issues are highly prevalent among perimenopausal and menopausal women, with many reporting the onset or exacerbation of symptoms during this life stage. Despite symptom burden, formal diagnoses and effective treatment remain limited. That’s the conclusion of a new study focused on gut health during the menopause transition. Results of the study will be presented at the 2025 Annual Meeting of The Menopause Society in Orlando October 21-25.

CLEVELAND, Ohio (Oct 21, 2025)—Hormone therapy–oral and transdermal–remains the most effective treatment for such bothersome menopause symptoms as hot flashes and is generally considered safe for most patients. A new study shows that risk profiles are different based on how the hormones are administered. Results of the study will be presented at the 2025 Annual Meeting of The Menopause Society in Orlando October 21-25.

CLEVELAND, Ohio (Oct 21, 2025)—Autoimmune diseases disproportionately affect women, with notable shifts in incidence following menopause, suggesting a potential role of sex hormones in immune regulation. A new study suggests a significantly higher incidence and risk of developing all autoimmune diseases (except Graves’ disease and autoimmune hepatitis) in postmenopausal women using hormone therapy. Results of the study will be presented at the 2025 Annual Meeting of The Menopause Society in Orlando, October 21-25.

Research shows that greater subjective well-being can lead to enhanced immune function and a lower incidence of chronic disease. But when does happiness start to exert its positive influence, and is there a point when this effect caps out? Researchers looked at national level data from 123 countries and found there is: on a scale from zero to 10, people started gaining health benefits once they surpassed a threshold that lies at around 2.7. Once above, each 1% of additional happiness could lead to a small decrease in mortality risk from non-communicable diseases.

This study analyzed 416 global Particle beam radiotherapy (PBRT) trials (2007–2023), revealing proton/carbon ion differences (Asia-focused, government-funded carbon ion; broader proton use), post-2021 trial decline, and early termination mainly from slow accrual. As the first global PBRT landscape analysis, it underscores needs for global collaboration, standardization, and larger trials to advance clinical application.

Indoleamine 2,3-dioxygenase 1 (IDO1) mediates breast cancer (BC) immunosuppression via tryptophan depletion, reducing effector T/NK cells and increasing Tregs/MDSCs, with higher expression in TNBC/HER2+. Current IDO1 inhibitors fail due to TDO/IDO2 compensation. Clinically, combining kynurenine pathway enzyme blockade may improve immunotherapy efficacy.